- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01759160
Hemodynamic Responses During Induction: Comparison of Marsh and Schnider Pharmacokinetic Models (TCI)
Hemodynamic Responses During Induction: Comparison of Marsh and Schnider Pharmacokinetic Models in Propofol Plasma Target-controlled Infusion
Study Overview
Status
Conditions
Detailed Description
Current systems of propofol TCI are pre-programmed with the Marsh and Schnider pharmacokinetic models. Rate constants of Marsh are fixed, whereas compartment volumes and clearances are weight proportional. Schnider model has fixed values for VC, V3, k13, and k31, adjusts V2, k12, and k21 for age, and adjusts k10 according to total weight, lean body mass (LBM), and height. One major benefit of the Schnider model is that it adjusts doses and infusion rates according to patient age. This provides a strong argument for using the Schnider model in the elderly and unwell patients which may improve hemodynamic stability and safety.
However for the vast majority of young and middle age patients, whether Marsh or Schnider would be a better choice for hemodynamic stability remains unknown.
With marsh model, as VC is scaled to body weight, the amount of drug delivered is dependent of body weight. In the Schnider model, as VC at 4.27L is independent of body weight, VC in terms of ml/kg decreases as body weight increases. This and the influence of height and weight on clearance results in heavier patients receiving less propofol on a mg/kg basis whereas those with a lower lean body mass will initially receive about 30% less than delivered by Marsh, but after 30 min, the Schnider model delivers about 15% more. Besides, when Schnider model is used in the morbidly obese, the LBM equation can generate paradoxical values resulting in excessive increases in maintenance infusion rates. Nevertheless, the purpose of this study was to investigate the vast majority of Asian patients whose body weight were in normal range. Only patients with BMI between 18 and 29 were included to minimize the influential factor of body weight in TCI system.
To compare the hemodynamic changes during anesthesia induction between Marsh and Schnider plasma TCI models. We put forward a hypothesis that, if one TCI model is associated with much more prominent vasodilation effect or cardiac depression, a more sharp decrease in mean arterial pressure, systemic vascular resistance , central venous return or stroke volume would be observed.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- The First Affiliated Hospital of Sun Yat-sen University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients between the ages of 18 years and 70 years
- ASA physical status I and II
- surgical procedures requiring general anesthesia with continuous CVP and arterial pressure monitoring.
Exclusion Criteria:
- Patients younger than 16 y or older than 65 y
- Body Mass Index (BMI) <18 or >30
- emergency surgery
- allergy to any of the drugs used
- inability to communicate effectively
- severe cardiovascular dysfunction
- patient refusal and patients on long-term opioids or sedative medication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Marsh
Marsh Plasma TCI with high initial target
|
plasma target-controlled infusion in Marsh model(n=30) with an initial target concentration of 4 μg/ml.
Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
Other Names:
|
|
Active Comparator: Schnider
Schnider Plasma TCI with high initial target
|
plasma target-controlled infusion in Schnider model(n=30) with an initial target concentration of 4 μg/ml.
Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SVI (Stroke Volume Index) Value Change From Baseline Level at the End of the First 25 Minutes.
Time Frame: The end of the first 25 minutes after propofol infusion
|
After propofol infusion started, according to sedation level, TCI targets were gradually titrated to reach a state of equilibrium at the end of the first 25 minutes.
SVI were continuously monitored, at the end of the first 25 minutes, value change from baseline level were calculated.
|
The end of the first 25 minutes after propofol infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NI (Narcotrend Index) Reduction
Time Frame: 25 minutes after propofol infusion
|
Narcotrend was utilized to continuously record patients' sedation level during induction, provided as a criteria for Cpt (Plasma Target Concentration) adjustment.
|
25 minutes after propofol infusion
|
|
CVP (Central Venous Pressure)
Time Frame: 25 minutes after induction
|
CVP was continuously monitored to assess preload condition and served to calculate SVRI (systemic vascular resistance index) every minute during the first 25 minutes of infusion.
|
25 minutes after induction
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xia Feng, M.D., The First Affiliaed Hospital of Sun Yat-sen University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- NSFCfengxiar1
- Fengxia1 (Other Grant/Funding Number: NSFC3140050)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.